Proteomics International Finalizes Corporate Restructure and Secures Exclusive Healius Distribution Deal for Promarker Diagnostics

Corporate Restructure Enhances Cost Efficiency and Commercial Focus

During the quarter, Proteomics International executed a strategic corporate restructure as part of its evolution from a research-driven entity to a commercially focused diagnostics company. Approximately nine positions were made redundant, representing about 25% of the workforce. This restructure is expected to generate annualised cost savings exceeding $1 million, providing financial flexibility to support key commercial initiatives.

Alongside organisational changes, Tim Luscombe was appointed Chief Financial Officer, in addition to his role as Company Secretary. Meanwhile, Neville Gardner retired from the Board after serving as Director and Chairman since November 2021. These changes align with the company’s strategic plan announced on 28 April 2026, positioning Proteomics International to pursue distributor-led commercialisation of its diagnostic portfolio while streamlining operations.

Healius Partnership Boosts Australian Market Penetration via 2,000+ Collection Centres

Following the June quarter, Proteomics International entered a national distribution agreement with Healius Limited, appointing Healius as the exclusive Australian pathology distributor for the Promarker portfolio. Effective 22 July 2026, the initial three-year term includes an option to extend for another three years by mutual agreement. This partnership leverages Healius’s extensive network of over 2,000 patient collection centres, facilitating specimen collection, pathology distribution, referrer engagement, and market access.

Proteomics International will continue conducting testing through its accredited laboratory facilities and provide clinical reporting. Implementation is underway, with a phased commercial rollout planned for FY27 following operational, laboratory, and IT integration. The Promarker portfolio remains in early commercialisation stages, and revenue projections under this agreement are currently indeterminate. Commercial terms remain confidential, with the company committed to updating the market on material developments per continuous disclosure obligations.

US Patent Grant Strengthens PromarkerEndo Intellectual Property Protection

After quarter end, the United States Patent and Trademark Office granted US Patent No. 12674806, titled "Endometriosis Biomarkers," to Proteomics International. This patent covers diagnostic methods using specific protein biomarkers in blood samples to detect endometriosis and guide treatment selection. The patent extends protection until March 2041, subject to maintenance, securing long-term IP rights for PromarkerEndo in the US healthcare market.

With patent protection now granted in the US and Japan, the company has fortified its IP position in key global markets. Additional patent applications remain in progress for other important jurisdictions. During the quarter, the company advanced PromarkerEndo assay validation and clinical protocol development to support clinical deployment and commercialisation in partnership with Healius and other channels.

PromarkerD Health Economics Publication Supports Reimbursement Strategy

Focus on PromarkerD, the diabetes biomarker test, centered on reimbursement readiness and evidence generation. The company published a US health economics manuscript in PharmacoEconomics, enhancing the evidence base for PromarkerD’s clinical and economic value. This supports efforts to establish reimbursement pathways and demonstrate value to payers and healthcare systems in the US market.

The peer-reviewed health economics data publication marks a significant milestone, as such evidence is critical for reimbursement approvals and adoption by healthcare providers. This complements the existing clinical evidence base and positions PromarkerD for future commercialisation and integration into clinical practice.

PromarkerEso Assay Refinement and Lab Protocol Optimization Advance Commercial Readiness

Proteomics International continued refining the PromarkerEso assay for oesophageal disease diagnostics and developed streamlined laboratory protocols. These efforts align with the strategy to prepare the Promarker portfolio for commercial deployment via Healius and other partners. Streamlined lab protocols enhance operational efficiency and consistency, essential for scaling testing across distributed collection centres.

The assay and workflow improvements reflect the company’s focus on operational excellence as it transitions from R&D to commercialisation, optimizing assay reliability, turnaround times, and cost-effectiveness to maintain competitive advantage and deliver value to healthcare providers and patients.

Strategic Review of OxiDx Technology Evaluates Commercial Development Pathways

During the quarter, Proteomics International initiated a strategic review of its OxiDx technology, assessing business models, product development needs, partnership and licensing opportunities, and other strategic options. This review aligns with prioritising resources toward the most commercially promising assets, particularly the Promarker portfolio.

Further investment in OxiDx will depend on commercial potential, capital requirements, and strategic fit. The review represents prudent portfolio management amid resource constraints and commercial transition. Investors should watch for updates on the review’s outcomes.

Laboratory Accreditations Renewed Under ISO 15189 and ISO 17025 Standards

Proteomics International successfully renewed its Australian laboratory accreditations under ISO 15189 and ISO 17025 following reassessment by the National Association of Testing Authorities (NATA). These accreditations are vital for pathology testing operations and support the credibility of test results among healthcare providers, payers, and regulators.

Quarterly laboratory activities focused on assay validation, procedure improvements, workflow consistency, and preparation for distributor implementation. Maintaining robust quality systems and regulatory compliance is fundamental to establishing Promarker tests as trusted diagnostic tools in clinical practice.

Cash Position at $3.50 Million Amid Restructuring-Related Outflows

Proteomics International ended the June 2026 quarter with $3.50 million in cash and cash equivalents, down from $5.69 million at 31 March 2026. Net operating cash outflows totaled $2.08 million, including approximately $0.46 million in one-time redundancy and entitlement payments related to the restructure.

Operating cash flows consisted of $1.09 million for staff, administration, and corporate costs; $0.87 million for R&D; and $0.29 million for manufacturing, operations, advertising, and marketing. The restructure is expected to reduce future quarterly outflows by over $1 million annually, enhancing cash sustainability. The current cash balance supports ongoing operations and the planned phased commercial rollout of Promarker tests via Healius in FY27, though further revenue growth or funding will be necessary to maintain operations and development.

Distributor-Led Commercialisation Strategy Drives Market Expansion

Proteomics International has shifted its commercialisation approach from direct market engagement to a distributor-led model, leveraging established pathology networks to accelerate market access and scale testing services. The Healius agreement is a key milestone, providing access to a national collection and distribution infrastructure that would be costly to build independently.

This strategy enables the company to capitalize on existing healthcare provider relationships and patient networks while retaining control over testing, quality, and clinical reporting. The approach aligns with the company’s streamlined operations post-restructure and is common in the in vitro diagnostics sector. Proteomics International continues to advance this model for the Promarker portfolio in the US, though no specific updates were provided in this quarterly report.